Archive for September, 2011

Strategic American Oil Corp. (SGCA) is “One to Watch”

Friday, September 30th, 2011

Strategic American Oil Corp. is an oil and natural gas exploration and production company with operations in Texas, Louisiana, and Illinois. Leveraging its technical expertise, promising portfolio and strong financial condition, the company is in an advantageous position to experience remarkable growth in the near term future by aggressively leasing, drilling, and acquiring projects at various stages of development.

To date, Strategic American Oil has established a land portfolio with an aggregate gross 5,236 developed and undeveloped acres in Texas and Illinois alone. With this acreage, the company has identified new exploration targets and is applying advanced technology to maximize production. The company has also leased land positions hosting previously producing wells with the goal of enhancing or reestablishing production.

In September 2011, Strategic American acquired SPE Navigation I, LLC, which included over $4 million in liquid assets and a $10 million working capital bank line, in exchange for shares in the company. The previous owners, who founded and developed Hyperdynamics Corp. (NYSE: HDY), now own an even greater stake in Strategic American Oil as a result of this acquisition. To date, these owners have provided more than 70% of the company’s capital for acquisitions and are committed to long term shareholder value.

Over the last twelve months, Strategic American Oil has significantly expanded its oil and gas production. Revenues are also increasing at a rapid rate, putting the company well on its way to becoming a mid-tier U.S. oil and gas developer. In addition to expanding its current projects, Strategic American Oil continues to seek accretive acquisitions of production, reserves and other companies with promising hydrocarbon prospects.

Let us hear your thoughts: Strategic American Oil Corp. Message Board

Threshold Pharmaceuticals, Inc. (THLD) Announces Initiation of Phase 3 TH-302 Combination Trial for Patients with Advanced Tissue Sarcoma

Friday, September 30th, 2011

Threshold Pharmaceuticals, Inc., in partnership with Sarcoma Alliance for Research through Collaboration (SARC), has announced the initiation of a Phase 3 randomized clinical trial of TH-302 in patients with soft tissue sarcoma. This pivotal international trial will enroll patients with metastatic or locally advanced unrespectable soft tissue sarcoma who have not received chemotherapy other then the adjuvant or neoadjuvant setting. The trial has been designed to evaluate the capability and the safety of TH-302 in combination with doxorubicin, in comparison to just doxorubicin alone.

Succeeding an end of Phase 2 meeting with the FDA, the Phase 3 protocol has been agreed upon under a Special Protocol Assessment (SPA). As a part of the assessment, the FDA has agreed that the planned analysis and the design of the study has adequately addressed the objectives that are necessary to support a regulatory submission needed for approval with enrollment anticipated to be completed by the end of the year 2013.

“Combining TH-302, a selective hypoxia-targeting prodrug, with doxorubicin, an agent with known activity in sarcoma, has a strong scientific rationale. TH-302 represents a novel concept in anti-cancer treatment. It was designed to deliver a cytotoxic agent to areas of a tumor that are often inaccessible to standard chemotherapies. We therefore expect that doxorubicin and TH-302 will complement one another by targeting the vascular components and hypoxic components, respectively, of a patient’s sarcoma,” said William D. Tap, M.D., Section Chief of Sarcoma Oncology at Memorial Sloan-Kettering Institute and principal investigator for this trial. “I’m excited to be a part of this collaboration between SARC and Threshold and I am looking forward to participating in this pivotal Phase 3 trial with the hope of establishing TH-302 as a new treatment for patients with sarcoma.”

“The proposed study is designed to confirm the encouraging results that we have previously reported in the Phase 1/2 study of soft tissue sarcoma patients treated with TH-302 in combination with doxorubicin,” said Sant P. Chawla, M.D., Sarcoma Oncology Center and principal investigator for the initial Phase 1/2 study. “The treatment of soft tissue sarcoma is a therapeutic challenge. Besides the approval of imatinib mesylate which was limited to gastrointestinal stromal tumors, there have been no new approved agents in first-line soft tissue sarcoma over the last 20 years. We look forward to working with Threshold and SARC.”

For more information on Threshold Pharmaceuticals Inc., visit their company website at http://www.thresholdpharm.com

Let us hear your thoughts below:

Intellect Neurosciences (ILNS), ViroPharma (VPHM) Ink Licensing Agreement

Friday, September 30th, 2011

Intellect Neurosciences Inc. today announced it has granted an exclusive license to ViroPharma Inc., in which the company will receive licensed patents and patent applications related to Intellect’s orally administered, clinical stage drug candidate, OX1.

ViroPharma plans to develop and commercialize OX1 to treat Friedreich’s Ataxia, a disease that causes nervous system damages and affects movement, as well as for the treatment of diseases for which OX1 may qualify for orphan drug designation.

“We are pleased to enter into a strategic relationship with ViroPharma, which has ample resources, drug development capabilities and orphan drug marketing expertise to accelerate the development and commercialization of OX1,” Dr. Daniel Chain, Intellect chairman and CEO stated in the press release. “This transaction is the first for Intellect related to an internally developed compound. It is consistent with our business strategy to create high value assets that can generate revenues to support further development of drugs for the ultimate benefit of patients in desperate need of novel treatments for life-threatening conditions.”

Per the agreement, ViroPharma will receive all of Intellect’s intellectual property rights and data related to Intellect’s OX1 research and development program in exchange for an up-front licensing fee of $6.5 million; furthermore, ViroPharma will pay additional milestones based upon defined events, at a potential maximum of $120 million. ViroPharma will also pay a tiered royalty based on annual net sales.

Intellect recently announced the completion of phase 1 clinical trials for OX1, in which the drug candidate was demonstrated as safe and well-tolerated across species.

For more information visit http://www.intellectns.com

Let us hear your thoughts below:

BeaconEquity.com: DoJ Investigation of 9 Chinese Companies triggers Sell-off

Friday, September 30th, 2011

Chinese companies trading on North American exchanges are once again in the regulatory spotlight; this time, it’s the Chinese Internet companies that are under fire.

According to reports, the U.S. Justice Department (DoJ) is investigating possible accounting frauds at a number of Chinese Internet companies trading on U.S. exchanges, which isn’t too much of a surprise considering swelling speculation regarding the legitimacy of Chinese stocks.

Keep your eye on these guys and trade at your own risk:

SINA Corp. (NASDAQ: SINA), Baidu.com Inc. (ADR) (NASDAQ: BIDU), Yoku.com Inc. (NYSE: YOKU), Focus Media (NASDAQ: FMCN), Sohu.com Inc. (NASDAQ: SOHU), Ctrip.com (NASDAQ: CTRP), E-Commerce China Dangdang (NYSE: DANG), Tawmee Holdings (NYSE: TAOM) and Tudou Holdings (NASDAQ: TUDO).

Let us hear your thoughts below:

BeaconEquity.com: Here’s Why the Gold Price Goes Higher

Friday, September 30th, 2011

In his latest interview with King World News, Euro Pacific Capital CEO said the U.S. economy is dropping quickly, gold will go much higher as a result of his bleak outlook, and the U.S. Treasury market is not a permanent safe haven for investors seeking shelter from market volatility brought on by sovereign bailouts, which, he added, will move across the Atlantic to the United States.

“We are going to fall off the edge of a cliff; it’s just a different cliff than most people are looking for,” Schiff told King World News’ Eric King. “I don’t think the stock markets are going to fall off the edge of a dollar cliff, or nominal cliff, but the US economy is going over the cliff.”

Schiff, the author of several financial books on the subject of investment strategies investors should take to preserve wealth during the ongoing global financial crisis, suggested one of the ways American investors can protect themselves from the crisis slated to come in the United States is to hold gold bullion.

Though the gold price can be volatile due to fund managers, governments and institutions liquidating gold to cover losses in other assets during the protracted crisis, gold, in the end, will remain as the ultimate safe haven as a store of wealth.

“Anything could happen in the short-run, but in the long-run, gold goes a lot higher,” Schiff explained. “Everything that is happening right now that is pushing the price of gold down, is actually bullish for the price of gold. That is why long-term the gold price will be higher.”

Just as famed commodities trader Jim Rogers of Rogers Holdings and Swiss money manager Marc Faber, publisher of the Gloom Boom Doom Report, Schiff’s betting on the Fed and U.S. Treasury to team up for providing further ‘stimulus’ to the U.S. economy in an effort to stave off a crisis in the U.S. dollar a little longer. That plan, he said, is the primary driver of the gold price—currency debasement to offset stagnant, or lower, GDP.

“We have this completely phony economy going, this bubble economy, it is still going to deflate and that hasn’t happened yet,” said Schiff. “The world is trying to keep the air in it, but ultimately the air will escape.”

In fact, the air has been escaping for quite some time, according to Jeffrey Gundlach of Los Angeles-based DoubleLine Capital.

Arguably the most respected bond fund manager, though lesser-known than PIMCO’s Bill Gross, the Wall Street Journal reported that Gundlach told approximately 100 financiers and reporters at a gathering at the New York Yacht Club, Thursday, “We’re in a recession right now.”

Co-founder & COO of Economic Cycle Research Institute (ECRI), Lakshman Achuthan, agrees. Earlier today, the leading business cycle research firm posted to its Web site, businesscycle.com, “Early last week, ECRI notified clients that the U.S. economy is indeed tipping into a new recession. And there’s nothing that policy makers can do to head it off.” (emphasis added).

Schiff expects the aborted recovery back to lower economic output in the U.S. spells doom for the U.S. dollar. Up till now, investors fleeing the euro into dollars will ultimately play out to have been the wrong move, according to Schiff.

“The dollar has been rallying, but I don’t think it should be,” he said. “The dollar is a risky asset. People are trying to hide out in dollars, in Treasuries, which are just future dollars, but I think that’s ultimately the riskiest place to move. These people who are buying dollars are making a mistake. People bought dollars in 2008, early 2009 and if they held them, they obviously lost a lot of money.”

“When we see an eventual precipitous decline in the dollar, you will see consumer prices rising and interest rates rising.”

Let us hear your thoughts below:

Universal Bioenergy (UBRG) Plans for OTC Bulletin Board Listing

Friday, September 30th, 2011

Universal Bioenergy Inc. is an independent, diversified energy company that is focused on producing and marketing natural and alternative energy products, including natural gas, petroleum, biofuels, synthetic fuels, wind, solar and related energy technology products.

The company today announced plans to be listed on the Over the Counter Bulletin Board (OTCBB) in order to expand its shareholder base and attract institutional investors. Universal Bioenergy has engaged the services of a financial consultant and a broker dealer/market maker to assist with the application and approval process.

The OTC Bulletin Board is a quotation service that displays real-time quotes, last sale prices, and volume information for over-the-counter securities. There are more 3,330 OTCBB securities, which include both U.S. and foreign equity issues, warrants, units, American Depositary Receipts (ADRs) and Direct Participation Programs (DPPs). It is regulated by the Financial Industry Regulatory Authority Inc. (FINRA).

The company’s senior vice president, Solomon Ali, said, “Having Universal’s common stock listed on the OTCBB is very important in our drive for greater sales and profitability.” Mr. Ali also believes that the OTCBB listing will allow Universal Bioenergy to raise more capital to grow the company. In addition, the company plans to list Frankfurt, Germany upon approval of the OTCBB listing.

For more information on Universal Bioenergy, please visit its website at www.universalbioenergy.com

Let us hear your thoughts below:

Washington Mutual, Inc. (WAMUQ) Video Chart for Friday, September 30, 2011

Friday, September 30th, 2011

Washington Mutual has been on a pretty hard slide for several months, but looks to be slowing down at this point.  If the current support at 7 cents falls, support should be strong at 6 cents.

To view the video chart, visit the following link: http://www.qualitystocks.net/videocharts

Let us hear your thoughts below:

SunOpta Inc. (STKL) Expands Aseptic Drink Capacity to Meet Increased Demand for Organic Beverages

Friday, September 30th, 2011

SunOpta Inc., a leading global company focused on natural, organic and specialty foods and natural health products, announced that it is expanding its non-dairy beverage production operations to meet the growing demand for aseptic, non-dairy beverages, broths and soups. SunOpta said that the expansion of the company’s Modesto, California plant will help meet the needs of existing clients plus accommodate the production of new private label, non-dairy, aseptic beverages planned to launch with a large club format retailer early next year. SunOpta specializes in processing, sourcing and packaging natural and organic foods like soy, sunflower, corn, fiber and fruit.

The expansion in Modesto, which should be completed in the third quarter of 2012, will increase production capacity by approximately 40 percent and the company’s overall aseptic non-dairy beverage and broth capacity by 10 percent. Once this capacity expansion is completed, SunOpta will have production capacity of between 250 and 300 million quarts of non-dairy beverages and broths, dependent upon product mix.

Currently, SunOpta produces natural and organic soymilk, rice beverages, almond beverages, plus hemp milk and broths. Plus the company recently launched its own sunflower beverage under the SOL (TM) brand name. The SOL sunflower beverage is made from sunflower seeds that are free from the eight most common food allergens including soy, dairy, wheat and tree nuts. The beverage, which is available in three flavors, is also an excellent supplier of key vitamins. SunOpta is one of the leading processors of confection sunflower seeds in the world and the development of a sunflower beverage adds further value to the Company’s vertically integrated production capabilities.

For more information, please visit www.sunopta.com

Let us hear your thoughts below:

Midas Medici Group Holdings, Inc. (MMED) Aims for Senior U.S. Exchange

Friday, September 30th, 2011

Midas Medici, a green-oriented IT solutions provider, announced today that it is actively seeking a listing on a senior U.S. stock exchange (NASDAQ or AMEX), once the company meets all applicable listing requirements. The move is meant to increase the company’s visibility in U.S. capital markets, and is a key part of their overall high-growth strategy.

Midas CEO and co-founder, Mr. Nana Baffour, commented on the announcement. “Graduating to a senior U.S. exchange is a high priority for Midas given the tremendous progress we have made growing our business through a combination of organic growth and accretive acquisitions in the United States and Brazil. Midas’ management team and our board of directors are confident that a senior listing will be of tremendous benefit to existing and potential shareholders. Not only would we expect a senior exchange listing to allow us to attract additional investors and increase liquidity, it would also make Midas available to a broader segment of the institutional community as we strive to make further improvements to our revenue, and enhance shareholder value.”

Midas supplies companies and institutions with virtualization, cloud computing, and data management solutions. The company helps optimize IT and data center investments, reducing data loss and cutting energy use, and also works with utilities in the U.S. and Brazil to improve the efficiency of the electric grid through the application of digital technologies.

Midas serves a diverse list of more than 700 clients, from mid-sized to Fortune 1000 companies. Midas’ comprehensive green IT and Smart Grid solutions are provided to customers around the world, including Pepsi, HP, Oracle, PBS, AT&T, Oracle, National Grid, the International Monetary Fund, and many more. The company’s stated mission is to become a leading global provider of green IT and Smart Grid solutions.

For more information on Midas Medici, please visit: www.MidasMedici.com

Let us hear your thoughts below:

Horizon Pharma, Inc. (HZNP) Appoints Grey and Pauli to Board of Directors

Friday, September 30th, 2011

Located in Northbrook, Illinois, Horizon Pharma is a biopharmaceutical company that commercializes innovative medicine that targets the unmet therapeutic needs in arthritis, pain and inflammatory diseases. Today, Horizon took another step forward with the announcement they have appointed industry veterans Michael Grey and Ronald Pauli to their Board of Directors.

Michael Grey received his bachelor’s degree in chemistry from the University of Nottingham in the United Kingdom. Since then, Grey has had an impressive career. Grey currently serves as president and chief executive officer at Lumena Pharmaceuticals, Inc. In a career that has spanned more than 3 decades, he has held senior positions at a number of other companies, including president and chief executive officer of SGX Pharmaceuticals, Inc. (sold to Eli Lilly in 2008), president and chief executive officer of Trega Biosciences, Inc. (sold to Lion Bioscience in 2001) and president of BioChem Therapeutic Inc.

Ronald Pauli received a bachelor’s degree in accounting from Michigan State University and went on to earn a master’s degree in finance from Walsh College. Pauli has led an illustrious career and is currently chief business officer at Sagent Pharmaceuticals, Inc., where he was recently promoted from his role as chief financial officer. As CFO, he played a key role in Sagent’s recent initial public offering. In addition, Mr. Pauli has held senior positions at a number of biopharmaceutical companies, including chief financial officer at NeoPharm, Inc. and corporate controller and interim chief financial officer at Abraxis BioScience, Inc., formerly American Pharmaceutical Partners, Inc. Mr. Pauli previously served as corporate controller for Applied Power, Inc. and R.P. Scherer Corporation and also held multiple finance positions at Kmart Corporation.

The appointments of Grey and Pauli come on the heels of Dr. Peter Johann resigning from the Horizon Board of Director’s after an impactful career with the company.

Leading the way at Horizon is Timothy P. Walbert whom serves as the Chairman, President and CEO of the Company. Walbert stated, “We are pleased to welcome Mike and Ron to our board. Their extensive pharma and biopharmaceutical experience in business development, finance and building companies will be an asset to our Board and beneficial to Horizon’s future growth.”

In reference to the resignation of Dr. Johann, Walbert commented, “On behalf of the Board of Directors of Horizon, I would like to thank Peter for his contributions to the Company’s journey to date and we wish him well in his endeavors.”

Currently, Horizon Pharma, Inc. is trading in the $7.48 range. To learn more about the company as a whole, visit their corporate website at: www.horizonpharma.com

Let us hear your thoughts below:

BeaconEquity.com: Is the QE Train Finally Coming?

Thursday, September 29th, 2011

Suddenly, the talk of the threat of deflation has coincidentally been put forward as a deep concern at the Fed. And the suggested remedy is, you guessed it, more quantitative easing. Ben has come to save us.

“It is something that we’re going to be watching very carefully,” Fed Chairman Ben Bernanke said in response to a question during a Q&A at forum sponsored by the Cleveland Fed.

“If inflation falls too low or inflation expectations fall too low, that would be something we have to respond to because we do not want deflation,” Bernanke said.

Like a corrupt dictator with ambitions of painting a perfect world for his nation, Bernanke has come to protect us from that lurking nemesis of state—deflation!

My, my, my … so soon after the FOMC meeting? Even after the markets were so hopeful of a Fed save, built up to a crescendo of excitement following the newsflash that a last-minute change in schedule, away from the normal 1-day FOMC meeting to an extended 2-day one was, instead, needed? Surely something big was afoot!

Bernanke surely needed that extra day to convince those three sticks-in-the-mud at the FOMC (as well as those disloyal Republicans so concerned about inflation) that inflation was less important than job growth, and that only he was destined to regain the glory of the 50-states by simultaneously averting a Wiemar style collapse of the dollar and a crushing Japanese-style lost double decade with his books in hand.

Well, Bernanke showed them all why he was destined to seize control of the hearts and minds of a fearful public plagued by a falling empire, didn’t he? He was so prescient when he said commodities prices were “temporarily elevated” by “transitory factors” and demonstrated single-handed why those three dissenters at the Fed are, in fact, enemies to the state.

It’s as if Bernanke was awarded divine understanding of what truly ails the great red, white and blue: it’s those evil speculators in the commodities pits who’ve got to be dealt with.

As in a 1933 Reichstag-like event, The Bernanke, as he is affectionately called, now, made sure commodities traders got their just due for their crimes—through a coordinated maneuver with its allies at the SNB to crush the Swiss franc at the precise moment the gold price was about to breakout to fresh all-time highs.

In an out-of-the-blue sale of a massive 4,000-gold futures position (naked short?) for December delivery which coincided with the SNB announcement, instead of the gold price soaring to $2,000, it was burned to the ground along with the franc.

And to permanently rid the state of those evil freegold speculators who misguidedly sought to flee the tyranny of theft, fear and persecution, The Bernanke led them to a train out of, they thought, the clutches of a dying fiat currency. Instead, the train whisked them to away to captivity and slaughter at the hands of a conniving ideologue.

The message is clear: the U.S. Treasury gets the carrot, gold gets the stick!

The salesman thanks the customer for patronizing his shop and asks him to come again. But the socialists say: Be grateful to Hitler, render thanks to Stalin; be nice and submissive, then the great man will be kind to you later too.

–Ludwig von Mises

And to top it off, injecting comic relief—in a gallows humor way—the Wall Street Journal publishes former vice chairman of the Fed, Alan Blinder (1994-96, another Princeton boy) piece (on the same day as Bernanke’s remarks in Cleveland) entitled, Ben Bernanke Deserves a Break.

The final outcome of the credit expansion is general impoverishment.

–Ludwig von Mises

Who needs a break?

Let us hear your thoughts below:

Small Cap Voice: Marley Coffee (JAMN) Enters Into Lucrative Monthly Membership Market with its “Marley Coffee Monthly” Program

Thursday, September 29th, 2011

Marley Coffee announced the launch of its “Marley Coffee Monthly” program at www.MarleyCoffee.com. This new program will allow consumers to select from its eight sustainable, organic, ethically produced coffee bean offerings and the frequency with which they would like to receive the beans: in one-month, two-month, three-month, or six-month intervals. For a limited time customers who spend over $30 on their initial coffee subscription will receive a free Bodum French press, a $30 value.

To celebrate the launch of the program, Marley Coffee will be donating to its charity, Kicks for a Cause, $1 for each new Marley Coffee Monthly signup for the next 30 days. This continues the company’s commitment to supporting charitable organizations through sales of products.

Rohan Marley, Chairman of Marley Coffee, said of the new venture, “We are looking forward to having Marley Coffee Monthly be a part of people’s daily lives. What makes our program special is its ease of use and the quality of the product. Customers can choose their level of commitment; modify their subscriptions at any time, and save money through free shipping. With the Holidays right around the corner, it makes a great gift that fans of Marley Coffee can feel good about giving.”

“This is going to be another important product channel that we can add to our lines of business. Some very large coffee companies got their start in the recurring food/ monthly club programs and we believe that we can become a major player in this extremely lucrative space,” added Brent Toevs, CEO of Marley Coffee.

Let us hear your thoughts below:

Sen Yu International (CSWG) Posts FY, Record Revenues on High Demand

Thursday, September 29th, 2011

Sen Yu International Holdings Inc., a leading commercial hog breeder and supplier in the People’s Republic of China, today announced improved financial results for its fiscal year 2011. The company said it is confidant its current operations and rising demand will generate continuing growth.

“We experienced record revenues and profits in fiscal 2011 based on strong demand for our high quality breeding and commercial hogs,” Zhenyu (Jack) Shang, founder, chairman and CEO of Sen Yu stated in the press release. ” … We believe our efficient business model and advanced breeding techniques, coupled with the demand we see for our products, will help us to continue to capture market share and drive our future growth.”

Revenue for the fiscal year ended June 30, 2011, increased 41.8 percent to a record $99.8 million compared to $70.4 million for the fiscal year ended June 30, 2010. The company attributes the increase to demand from its existing major customers, Beijing Dahongmen and Beijing Fifth Meat Factory.

Gross profit for the fiscal year ended June 30, 2011, increased 84.6 percent to $11.9 million compared to $14.0 million for the fiscal year ended June 30, 2010. Gross margin for fiscal 2011 increased to 26.0 percent from 20.0 percent for fiscal 2010.

Sen Yu reported that operating expenses for fiscal 2011 decreased 12.2 percent to $6.9 million from $7.9 million for fiscal 2010.

The company’s operating income for the fiscal year ended June 30, 2011, increased 207.4 percent to $19.0 million from $6.2 million for the fiscal year ended June 30, 2010.

Net income for 2011 increased to $36.1 million, or $1.40 per diluted share, which includes a gain of $17.2 million related to the change in the fair value of warrants, compared to $4.3 million, or $0.29 per diluted share, for 2010, which includes a non-cash expense of $2.0 million related to the fair value of warrants.

As of June 30, 2011, Sen Yu had $11.4 million in cash and cash equivalents, an increase of 96.4 percent from $5.8 million as of June 30, 2010, and $59.2 million in working capital, an increase of 189.6% from working capital of $20.5 million at June 30, 2010.

Moving forward, broader factors contribute to the company’s optimistic expectations.

“We see significant growth for our industry going forward and believe that strong demand from Chinese consumers for high quality pork coupled with rising domestic incomes and economic expansion will stimulate even greater demand for our high quality breeding hogs,” Shang stated. “The market for breeding and commercial hogs is becoming very attractive to foreign investors as China is the world’s largest consumer of pork and produces some 50 million tons of pork every year to feed a population of over 1.3 billion. We continue to expand our production and refine our breeding techniques to meet the rising demand from China’s middle class. Going forward, we believe pork consumption and production will continue to rise and that Sen Yu is well positioned to capture greater revenue and profit.”

For more information visit http://www.hljsenyu.com

Let us hear your thoughts below:

Tri-Tech Holding Inc. (TRIT) Secures $1.87M CCTV Production Security Project for New Petroleum Industrial Park in Shaanxi

Thursday, September 29th, 2011

Tri-Tech Holding, long known as a leading developer of sophisticated turn-key sewage treatment/odor control solutions for some of China’s top municipalities/cities and wielder of an impressive portfolio of intellectual property (2 patents, 27 software copyrights to date), announced that affiliate Beijing Satellite Science & Technology Co., Ltd. (BSST) has secured a $1.87M public bid with the Yanchang Petroleum Group to provide operational/security TV monitoring at a new industrial park in Shaanxi.

The Jingbian Energy and Chemical Industrial Park in Jingbian County, currently under development by Yanchang, will be comprised of a total of six petroleum refining/post-processing plants, collectively capable of yielding million of tons per year of high-value intermediate petroleum products.

TRIT affiliate BSST has been tasked with the essential mission of providing comprehensive CCTV infrastructure, in order to ensure that production security is maintained. The approach outlined by BSST will take the form of a two-pronged systems implementation, with one prong handling production/operational concerns and the other covering perimeter security.

A huge job and a huge boon for BSST, who will provide everything from the design, to materials and implementation/operator commissioning, leveraging the Company’s vast experience in system integration and project installations to deliver by a projected completion date of May, 2013.

CEO of TRIT, Warren Zhao, applauding this second production safety project secured by BSST through Yanchang, spoke of the exemplary progress made thus far with the initial Yanchang project, asserting that the work prompted Yanchang to engage BSST for additional help. Zhao noted that the initial Yanchang project was on schedule for Oct. 2011 completion and pointed to a broadening international focus at TRIT, briefly mentioning ongoing industrial wastewater treatment opportunities being pursued in North America via their Wisconsin-based, J&Y Water Division.

Zhao also pointed to ongoing business development efforts in the Middle East and India, assuring investors that the Company would offer timely press releases concerning prevailing developments with such active bids.

President of TRIT, Gavin Cheng, echoed his colleague’s sentiments roundly and went into greater detail on the industrial CCTV system to be utilized, highlighting in particular the powerful fusion of long range imaging technology and environmental sensors. Cheng underscored the operational benefits of such a system that can detect equipment malfunctions in order to prevent accidents, as well as monitoring production continuously, enabling spills or leakages to be identified and handle if they do occur before the situation gets any worse. Cheng emphasized the importance of such a system to the overall secure operation and performance of the industrial park, and pledged to maintain strict oversight.

For more information on the project, or to find out more about Tri-Tech Holding Inc., please visit the Company’s website at: www.Tri-Tech.cn

Let us hear your thoughts below:

Consorteum Holdings, Inc. (CSRH) Uses Card Technologies to Fill Gaps in Worldwide Financial Services

Thursday, September 29th, 2011

When Consorteum Holdings announced earlier that it was launching an innovative MasterCard® program, targeting the Canadian Aboriginal communities, it was a reflection of the company’s overall strategy to fill large gaps in the provision of comprehensive financial services to all segments of the population. In the case of the First Nations MasterCard Program, it was a major move to make life easier for a significant national community.

The card functions much like any MasterCard. Pre-loaded with authorized funds, it is available to anyone, and offers a more efficient and safer way to transfer funds to individuals than by issuing checks, which can be lost or stolen, and which can be difficult to cash if you don’t happen to have a local bank account. As with a regular MasterCard, purchases can be made virtually anywhere, with the amount of the purchase simply being deducted from the card’s balance. The card can also be used for obtaining cash at participating ATM machines.

From a larger perspective, Consorteum’s products represent the application of the latest digital technologies, together with key connections within the financial industry, to help companies and organizations more efficiently transfer payments and process transactions. Other applications include the development of customized loyalty programs for clients, where card technology is used to reward loyal customers, or providing healthcare patients with card-based systems for tracking and managing health records and transactions. The company also makes it easy for ship operators to pay international employees that require different currencies.

More than a simple financial service, it can change lives. It was perhaps best said by Rudy Youngblood, a Native American who has spent much of his life raising the profile of Native American communities throughout Canada and the United States: “This journey presents a once in a lifetime opportunity to be part of a program that will change history. This is something I have been fighting for all of my life and to provide the Tribal regions with access to a full suite of financial services is tremendously empowering.”

For more information, visit www.Consorteum.com

Let us hear your thoughts: Consorteum Holdings, Inc. Message Board

BeaconEquity.com: Zhongpin Trending Higher

Thursday, September 29th, 2011

Zhongpin Inc. shares nudged higher this morning, lifted by the overall market. The China-based meat and food processing company last month announced that its board of directors authorized an increase in the share buyback program of 30 million of its outstanding shares over the next 12 months.

Under a share buyback program, which came into effect last month, the company has authorized to buyback up to $40 million of its issued and outstanding shares of common stock from time to time. Xianfu Zhu, chairman and CEO of Zhongpin, said last month that the company has strong confidence in its growth prospects as the Chinese economy continues to grow and its industry consolidates further.

Zhongpin also released its second-quarter financial results last month. The company reported a 70% increase in second-quarter revenue to $366.5 million. The company’s gross margin for the second quarter of 2011 was 10.7%, compared with 11.8% reported in the same period in the previous year. The company reported net income of $19.3 million for the second quarter, up 56% over the same period in the previous year.

Zhongpin shares fell 12.11% since the release of second-quarter financial results last month. Year-to-date, the stock is down 60.32%.

Let us hear your thoughts below:

China Precision Steel, Inc. (CPSL) Reports Strong Increase in Sales

Thursday, September 29th, 2011

China Precision Steel, Inc. reported higher year over year sales in the fourth quarter of fiscal 2011, as the company benefited from strong demand for many of its product lines.

China Precision Steel reported sales of $46 million in the quarter ending June 30, 2011. This was a 27% year over year increase from the corresponding quarter of 2010, and a 46% sequential increase from the third quarter of fiscal 2011.

China Precision Steel volume also showed a sharp year over year increase, with sales of 49,104 tons in the most recent quarter. This was a 26% increase over the 39,112 tons sold in the fourth quarter of fiscal 2010.

China Precision Steel attributed the better results to strong demand for the company’s cold-rolled steel products. The company manufactures and sells low carbon cold-rolled steel for applications in the home appliance and packaging industries, and high carbon cold-rolled steel for use in the automotive industry.

China Precision Steel said that sales of these two types of products now account for 93% of company sales, down from 98% in the same quarter in fiscal 2010. The company ended the quarter with a $25.6 million backlog of orders.

For more information on the company, go to www.chinaprecisionsteelinc.com

Let us hear your thoughts below:

GreenWorld Development, Inc. (GREW) Announces Plan to Develop Waste to Energy Power Plants

Thursday, September 29th, 2011

UK-based GreenWorld Development Inc. released news today announcing its plan to develop and build 200MWT of utility scale Waste to Energy Power Plants across the United States, Europe and Asia until 2016. The development plan catapults GreenWorld Development into this fast growing sector as an up and coming global player. When completed, the projects will potentially treat over 700,000 tons of waste and generate revenues in excess of $250 million US dollars.

The company’s first UK Waste to Energy Centre will be based in Market Warsop in Nottinghamshire. The site consists of 2.5 acres and offers sufficient space for the installation of the “Tyre to Energy” plant and CHP. Projections estimate that these components will generate 7MW of renewable energy. The Market Warsop site’s waste transfer license allows it to take in 100 tons of tyres per day, providing adequate feed stock for the planned energy generation. It can also accommodate storage of 500,000 tyres. GreenWorld also is negotiating licenses in the UK and United States in addition to the development of its OHIO facilities.

According to Leo J. Heinl, GreenWorld’s CEO, the company plans to grow its business organically as well as through merger and acquisition of existing facilities in the target markets aiming at creating a consolidated global portfolio of utilities. In a global market expected to reach $28.8 billion USD by 2015, and with very few international players on a utility scale, GreenWorld is aimed to become a key player in this market.

“The company is proud to announce the engagement of a professional team with solid global expertise to drive and to support the company’s mission and growth strategy. Further and additional management members will join the team soon,” remarked Mr. Heinl.

Let us hear your thoughts below:

AgriSolar Solutions, Inc. (AGSO) Introduces Solar Insect Elimination Systems to Europe

Thursday, September 29th, 2011

AgriSolar Solutions, Inc. recently announced that it would be opening several sales and distribution offices in Europe for the purpose of introducing its solar powered insect elimination systems to the market. These systems will be rolled out for use on farms, orchards and vineyards.

Based in Colorado, AgriSolar Solutions manufactures and distributes an eco-friendly pesticide-free insect elimination system, with the goal of making pesticides obsolete. Insect control is a $70 billion industry worldwide, with the most inexpensive chemical insecticides costing approximately nine dollars per acre per month. Organic insecticides, while being more eco-friendly than non-organic insecticides, average at sixty dollars per acre per month. Conversely, the AgriSolar insect control system costs one dollar per acre per year.

While AgriSolar has a foothold in the Chinese market, European legislation known as the Pesticides Framework Directive dictates the sustainable use of pesticides, aiming to reduce the impact of pesticides on human health. In this area, AgriSolar has seen exceptional growth during recent periods.

Revenue for the three-month period ending June 30, 2011 was $5.6 million, a 147% increase from the previous quarter that ended in March 2011, and a 90% increase on a year-over-year quarterly basis. Gross profit increased to $1.6 million from $1.0 million during the previous year. Quarterly comprehensive income for the quarter was $423,482, or $.01 per share (basic), compared to a loss during the June 2010 quarter. Along with AgriSolar’s expansion into Europe, the company is also planning similar growth in North and South American markets.

AgriSolar’s CEO Liang Chao Wei, said, “The time is right for us to significantly expand our distribution considering the push to implement Europe’s Pesticide Framework Directive, which aims to reduce the risks and impacts of pesticides on human health. Our state-of-the-art insect control systems have seen great success in the Chinese agricultural market, which has allowed us to grow our revenues very quickly. Additionally, we have recently added a meaningful amount of additional manufacturing capability that will allow us to produce in the volumes necessary to satisfy the additional strong demand we are expecting within the European market.”

Let us hear your thoughts below:

SupportSave Solutions, Inc. (SSVE) Leverages Efficiencies to Offer a Full Array of Business Services at Competitive Prices

Thursday, September 29th, 2011

SupportSave Solutions Inc. provides onshore and offshore business process outsourcing (BPO) from service delivery centers centrally located in the Philippines. This location, Cebu City – the second largest city in the islands, and ranking at the top of Asian cities in terms of BPO functions – offers business services to clients in the travel and hospitality industries, as well as those in banking and financial services, insurance, technology, retail, and telecommunications industries.

SupportSave is able to provide comprehensive and effective offshore business service delivery service at affordable prices thanks to its complete familiarity with the Philippines labor market. This expanded understanding of the supply side of BPO has allowed SupportSave to create fully functioning service centers to deliver fully redundant voice and data business services via backup links and secondary connections. SupportSave also boasts an enterprise-grade network infrastructure with robust connectivity, redundant generator sets to insure that all that connectivity is deliverable, and a host of other features that U.S. and multinational corporations have come to expect of any large BPO provider.

Unlike others, however, SupportSave provides these services without the bulky overhead and weighted cost structures, by controlling the expenditures that otherwise typically go into infrastructure, technology and labor management. This allows the Company to offer BPO services like contact center and back-office support at a substantial discount as compared with other BPO service providers on the Indian subcontinent or in the Philippines.

The Company’s financial strength is easily verified and its management and business practices completely transparent, thanks to a skilled executive team that has transitioned quite a number of large (multi-million-dollar) projects for various, easily recognized multinationals in banking, travel, insurance and other sectors. In fact, SupportSave offers all the in-depth services and features of much larger BPOs, but at less than half the cost, thanks to its intense focus on cost-efficient business-process modeling and smart spending.

These features include superior customer service from an array of call centers, and extensive back-office support services like routine administrative tasking, database building, data entry, document management and technical support. It is this array of functions that allows SupportSave to help businesses deliver the sort of customer experience that drives brand loyalty and supports incremental revenue growth while still saving on operating costs.

But the Company offers more than cost savings, or reduced total cost of ownership (TCO). It also offers flexibility toward process enhancement, improved voice-of-the-customer record integration, and overall deal structuring, which larger firms can’t manage because their size creates a certain inherent functional rigidity.

SupportSave’s cost savings are achieved by strategic geographical location of service centers and a frugal yet sensible approach to provisioning them. These savings are further enhanced by using open-source technologies and platforms rather than expensive licensing strategies, and by streamlining delivery infrastructure with technological innovations as they become available.

It is thanks to this wide-ranging yet affordable BPO structuring that SupportSave is currently supplying customer service and technical support to a leading home appliance original equipment manufacturer (OEM); providing research services for an online brand preservation agency; providing technical support for several software-as-a-service (SaaS) firms; providing lead generation for sales by a private equity firm; and delivering back-end staffing services (job posting, online support) for a major employment agency.

These are only a few examples of the services that the Company can offer. SupportSave can also deliver cost-effective blog updating, data mining, ad posting, order processing, resume formatting, interview scheduling for job seekers, and – in the real estate field – property listing, appointment setting, and foreclosure status confirmation, among other things.

The Company also offers medical business services, from scheduling patient tests to follow-up and reminder calls, screening, billing and collections – all services that SupportSave can provide for a cost of $897 per full-time employee per month, on a 24/7 time frame, which equates to $5.18 per hour – a flat-rate model that makes outsourcing financially feasible even for small businesses.

SupportSave plans to use this lean but effective business model to grow both organically, by acquiring new customers, and through acquisitions in the same vertical, some of which the Company’s management team has already identified. The growth should be easy to achieve, thanks to SupportSave’s full range of BPO services, highly competitive rates, and a level of quality and reliability that drives its own brand loyalty.

Let us hear your thoughts: SupportSave Solutions, Inc. Message Board

FITT Highway Products Inc. (FHWY) ‏is “One to Watch”

Wednesday, September 28th, 2011

FITT Highway Products, Inc. is a brand management Company that lists on the OTC Bulletin Board. FITT has entered into an Operating Agreement with F.I.T.T. Energy Products Inc. to perform a majority of their operating services. This includes, among other things, selling, marketing, producing, and distributing the “F.I.T.T. Energy Shot With Resveratrol”. F.I.T.T. Energy Products will pay the Company a royalty for each energy shot sold. FITT Highway Products has their corporate headquarters in Mission Viejo, California.

The Company focuses on customers in their twenties, thirties, and forties, who have an interest in fitness and health, as well as gaining an energy boost. FITT’s intention is to market their products through their retail outlet, a website, as well as through a direct response television presence.

In July, FITT announced that F.I.T.T. Energy Products (F.I.T.T.), a non-affiliated operating partner, began discussions with their medical experts, key investors, attorneys, and media partners to identify a large pharmaceutical or beverage partner to rollout “F.I.T.T. Energy With Resveratrol” energy shots to the retail marketplace. The basis of the decision to speed up the rollout was on positive preliminary results of their completed double blind crossover study involving two leading competitors’ products.

This week, FITT Highway Products announced F.I.T.T. Energy Products completed their randomized, single center, double blind, crossover trial to evaluate the impact of the “F.I.T.T. Energy With Resveratrol” energy shot and two leading competitors’ products on resting blood pressure. Final results indicate the F.I.T.T. Energy shot did not statistically elevate systolic blood pressure over the placebo. The completed test results revealed that competitors’ energy shots caused average increases in patients’ systolic blood pressure in amounts 224 percent to 355 percent greater than when taking F.I.T.T. Energy.

Additional raw data from the study indicated F.I.T.T. Energy produced a significantly less “jittery feeling” in the test subjects than the competitive products. Moreover, F.I.T.T. Energy was able to achieve an “energized feeling” in the test subjects with less than one-half the caffeine content of the competitive products.

Let us hear your thoughts below:

BEFUT International (BFTI) Posts Q4, FY2011 Increases

Wednesday, September 28th, 2011

BEFUT International Co. Ltd., a developer, manufacturer and distributor of wire and cable products in China, today announced its financial results for the fiscal year ended June 30, 2011.

The company’s positive fourth quarter and full-year 2011 were fueled by several variables, including increased demand for the company’s current product offerings, as well as several patent pending products.

“We are pleased to report strong growth in revenue and net income for fiscal 2011. Our product strategy, marketing strategy and strong R&D have been key drivers to our success. We continue to grow our traditional cable business, but are particularly focused on increasing sales of our higher margin products such as carbon fiber composite cable, submarine cable and certain ‘new energy’ cables, including cable for wind and solar energy,” Hongbo Cao, chairman and CEO, BEFUT stated in the press release. “We have been awarded a number of new patents and now have 17 approved patents and 45 pending, which provide us an important competitive advantage.”

The company reported fourth-quarter revenue for the three months ended June 30, 2011, at $15.4 million compared to $11.9 million for the fourth quarter ended June 30, 2010. BEFUT attributes the increase to growing demand across all product lines. Gross profit was $4.2 million for the fourth quarter of 2011 compared to $3.1 million for the fourth quarter of 2010. Fourth quarter 2011 operating income was $1.7 million compared to $0.9 million for the three months ended June 30, 2010. Net income for the three months ended December 31, 2010, was $4.5 million, or $0.07 per diluted share, compared to net income of $2.1 million, or $0.03 per diluted share, for the same period last year.

Revenue for the 12 months ended June 30, 2011, was $55.6 million compared to $31.3 million for the comparable 12 months of 2010. Gross profit was $14.9 million for fiscal year 2011 compared to $8.3 million for the comparable 12 months of 2010. Operating income was $9.0 million for the 12 months of 2011 compared to $4.3 million for the 12 months ended June 30, 2010. Net income for the full fiscal year ended June 30, 2011, was $9.4 million, or $0.33 per diluted share, compared to net income of $4.4 million, or $0.15 per diluted share, for the same period last year.

“We have established a first class customer base encompassing many of the largest conglomerates in China—spanning ship building, nuclear power, mining, petrochemical and other industries,” Cao continued. “Given our proven track record, established brand and premier customer base, we look forward to expanding our sales by aggressively adding new sales reps and new sales offices across China, in addition to new initiatives underway to grow our international sales.”

Let us hear your thoughts below:

YM BioSciences, Inc. (YMI) Begins Phase II Trial for Its CYT387 Drug

Wednesday, September 28th, 2011

YM BioSciences Inc. is a drug development company. It is currently advancing three clinical stage products: CYT387, a small molecule, dual inhibitor of the JAK1/JAK2 kinases; CYT997, a vascular disrupting agent; and nimotuzumab, an EGFR-targeting monoclonal antibody.

The company today announced that it has enrolled the first of 60 patients in its Phase II trial of CYT387. The drug is to be administered twice daily for the treatment of myelofibrosis. The trial is intended to further evaluate the safety and tolerability of YM BioScienes’ JAK1/JAK2 inhibitor, as well as its efficacy in reducing spleen size, improving symptoms and reducing transfusion dependence in patients with the disease.

In an ongoing Phase I/II trial, CYT387 appears to have a favorable safety profile and has produced a clinically beneficial response in a number of patients. Initial data from this new trial will be used to further enhance YM BioSciences’ pivotal trial designs. The company will acquire additional safety and efficacy data for the drug at doses complementary to those evaluated in the ongoing 166 patient trial.

YM BioSciences’ president and CEO, Dr. Nick Glover, added, “The substantial volume of patient data from the combined studies will be an important component of any future marketing application.”

For more information on YM BioSciences and its CYT387 drug, please visit the company’s website at www.ymbiosciences.com

Let us hear your thoughts below:

TiVUS, Inc. (TIVU) Lets You Take Home Preferences with You

Wednesday, September 28th, 2011

When you’re at home, what kind of electronic entertainment and computer setup do you prefer? The capabilities and arrangement of your home systems says a lot about you, the way you work, how you watch television, the way you communicate with the world. But then what’s it like when you’re on the road? Do you find yourself trying to cobble together limited hotel resources in an effort to get your work done or keep the family happy? Do you find yourself thinking how much easier it is at home, where you perhaps like to work on the Internet through your television, or watch Netflix and other video streaming sites on a big screen?

If so, you’re not alone. As home communication and electronic functionalities become more flexible and powerful, more people find themselves disappointed by the limitations of traditional hotel services. The idea of a pricey hotel, or even a resort, having antiquated electronic resources is becoming a major factor in travel decisions, and a threat to hotel revenues. Comprehensive access to the Internet, for example, is now considered a necessity, not a luxury.

TiVUS, a hospitality industry entertainment services and technology company, has created the first-of-its-kind Internet protocol HDTV system for hotels and resorts. For guests, it represents all of the flexibility and capability of home, together with added features for hotel communication.

• Entertainment centers can be tailored to each guest, regardless of where they travel, thanks to a TiVUS patented customer identification system.
• Guests have full access to all local and cable channels, plus all of the latest movies.
• Laptops and even mobile devices can be connected to the TiVUS system, allowing viewing of Netflix, Hulu, and other video streaming sites through the big screen television.

For the hotel, the TiVUS ad revenue business model allows revenue to be generated in ways never before possible. Special licensing agreements with content providers allow the delivery of normal advertising on a shared-income basis. In addition, IPTV and integrated software technology and algorithms allows the targeting of specific demographic viewers, serving ads based upon viewer preferences, resulting in a highly focused and valuable way for advertisers to reach the market. The system is already being installed in major hotels, with plans for worldwide expansion.

For more information, visit the company’s website at www.Tivus.com

Let us hear your thoughts: Tivus, Inc. Message Board

BeaconEquity.com: Elite Pharmaceuticals (ELTP) Allergy Product Launch Triggers 30% Gains

Wednesday, September 28th, 2011

Shares of Elite Pharmaceuticals Inc., a specialty pharmaceutical company, soared in yesterday’s trading after the company, along with ECR Pharmaceuticals, announced the launch of Lodrane D®, an immediate release formulation of brompheniramine maleate and pseudophedrine HCI.

The product will be manufactured by Elite, and promoted and distributed by ECR in the U.S. It will be available over-the-counter. Elite will be entitled to revenues for the manufacturing, packaging and laboratory study services of the product, as well as royalties on sales. With the U.S. allergy market currently estimated at $3.5 billion, the product has huge potential.

Jerry Treppel, chairman and CEO of Elite, said that Elite and ECR worked diligently to provide a Lodrane product to U.S. consumers. Treppel further said that with the launch, the company looks forward to rebuilding the important allergy-relied franchise. He added that the company will continue to build and leverage its technologies through its product pipeline, partnerships and ventures as it continues to systematically meet the milestones it has set.

Let us hear your thoughts below: